FDA Gene Therapy IND/BLA Consulting in 2023: CMC Control Strategy and Risk Mitigation FDA Gene Therapy IND/BLA Consulting in 2023: CMC Control Strategy and Risk Mitigation As the field of gene therapy rapidly advances, navigating the regulatory landscape set forth by the FDA becomes increasingly complex. For professionals in Regulatory Affairs, Clinical Development, and Quality Assurance, understanding the sequential steps needed to comply with the requirements for Investigational New Drug (IND) Applications and Biologics License Applications (BLA) is essential. This article serves as a comprehensive guide to gene therapy regulatory consulting, focusing on Chemistry, Manufacturing, and Controls (CMC) strategies, as…

Long-Term Follow-Up (LTFU) Plan for Gene Therapy in 2023: US FDA Expectations and Templates Long-Term Follow-Up (LTFU) Plan for Gene Therapy in 2023: US FDA Expectations and Templates Long-Term Follow-Up (LTFU) plans in the context of gene therapies are critical to ensuring patient safety and efficacy monitoring over extended periods post-administration. In the United States, the Food and Drug Administration (FDA) has outlined specific expectations regarding LTFU plans in gene therapy applications. This tutorial provides a comprehensive, step-by-step guide that regulatory professionals can implement to understand and create effective LTFU plans for their gene therapy products. Step 1: Understanding the…

AAV Vector Manufacturing CMC Strategy in 2023: Critical Quality Attributes and Release Tests AAV Vector Manufacturing CMC Strategy in 2023: Critical Quality Attributes and Release Tests This article serves as a comprehensive guide for professionals involved in the development and commercial production of adeno-associated virus (AAV) vectors for gene therapy. The focus is on the Chemistry, Manufacturing, and Controls (CMC) strategy necessary for regulatory submissions such as an Investigational New Drug (IND) application and Biologics License Application (BLA) in the United States. Emphasizing practical actions, documentation expectations, and compliance with FDA guidelines, this tutorial delineates the critical quality attributes (CQAs)…

Environmental Assessment (EA) / ERA Strategy for GMO Gene Therapy in 2023: Submission Checklist Environmental Assessment (EA) / ERA Strategy for GMO Gene Therapy in 2023: Submission Checklist The regulatory landscape for gene therapy products, particularly those utilizing genetically modified organisms (GMOs), demands rigorous attention to environmental considerations. Of utmost importance for developers in this sector is the Environmental Assessment (EA) and Environmental Risk Assessment (ERA). This comprehensive guide presents a step-by-step methodology for conducting EA/ERA for gene therapy products, ensuring compliance with U.S. regulatory requirements and best practices. Step 1: Understanding the Regulatory Framework Before proceeding with an EA/ERA…

Immunogenicity Risk Management for Gene Therapy in 2023: Regulatory-Ready Evidence Pack Immunogenicity Risk Management for Gene Therapy in 2023: Regulatory-Ready Evidence Pack The development of gene therapy products requires rigorous adherence to regulatory frameworks, particularly concerning immunogenicity. Proper management of immunogenicity risks is crucial in ensuring the safety and efficacy of gene therapy products. This article provides a comprehensive, step-by-step guide for regulatory professionals involved in the development of gene therapies, including IND and BLA submissions. We will cover key components from initial considerations to post-approval commitments, with a focus on compliance with FDA guidelines. Step 1: Understanding the Regulatory…